A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

Yoshifumi Takei; Kenji Kadomatsu; Yukio Yuzawa; Seiichi Matsuo; Takashi Muramatsu

doi:10.1158/0008-5472.CAN-03-2682

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

Yoshifumi Takei, Kenji Kadomatsu, Yukio Yuzawa, Seiichi Matsuo, Takashi Muramatsu

Research output: Contribution to journal › Article › peer-review

366 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.

Original language	English
Pages (from-to)	3365-3370
Number of pages	6
Journal	Cancer Research
Volume	64
Issue number	10
DOIs	https://doi.org/10.1158/0008-5472.CAN-03-2682
Publication status	Published - 15-05-2004
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/0008-5472.CAN-03-2682

Cite this

@article{4a4f204946e5489fa3885ff918024626,

title = "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics",

abstract = "Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.",

author = "Yoshifumi Takei and Kenji Kadomatsu and Yukio Yuzawa and Seiichi Matsuo and Takashi Muramatsu",

year = "2004",

month = may,

day = "15",

doi = "10.1158/0008-5472.CAN-03-2682",

language = "English",

volume = "64",

pages = "3365--3370",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

TY - JOUR

T1 - A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

AU - Takei, Yoshifumi

AU - Kadomatsu, Kenji

AU - Yuzawa, Yukio

AU - Matsuo, Seiichi

AU - Muramatsu, Takashi

PY - 2004/5/15

Y1 - 2004/5/15

N2 - Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.

AB - Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.

UR - http://www.scopus.com/inward/record.url?scp=2442668068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442668068&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-2682

DO - 10.1158/0008-5472.CAN-03-2682

M3 - Article

C2 - 15150085

AN - SCOPUS:2442668068

SN - 0008-5472

VL - 64

SP - 3365

EP - 3370

JO - Cancer Research

JF - Cancer Research

IS - 10

ER -

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this